Brief: Lonza Expands Dual-Payload ADC Technology Offering Through Access To Qurient's CDK7 Inhibitors
12/10/2026 13:04
BRIEF-Lonza Expands Dual-Payload ADC Technology Offering Through Access To Qurient's CDK7 Inhibitors Oct 12 (Reuters) - LONZA GROUP AG LONN.S:
EXPANDS DUAL-PAYLOAD ADC TECHNOLOGY OFFERING THROUGH EXCLUSIVE ACCESS TO QURIENT'S CDK7 INHIBITORS
Source text: ID:nEQ5Qtjp1a
Further company coverage: LONN.S
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 587785269;))
Recent news on Qurient
See all newsBrief: Lonza Expands Dual-Payload ADC Technology Offering Through Access To Qurient's CDK7 Inhibitors
Brief: Qurient To Conduct Capital Increase Of 8 Billion Won For Operational Funds
Brief: Qurient Therapeutics Enters Crada With The National Cancer Institute To Collaborate On A Phase 1/2 Clinical Study Of Q901 In Combination With Trop2-Adc
Brief: Qurient Announces Dosing Of First Patient In Q901 Phase 1/2 Clinical Study For The Treatment Of Patients With Solid Tumors
Brief: Qurient Announces Collaboration Agreement With MSD